PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.

Gralewska, Patrycja; Gajek, Arkadiusz; Marczak, Agnieszka; Mikula, Michal; Ostrowski, Jerzy; Sliwinska, Agnieszka; Rogalska, Aneta

Gralewska, Patrycja; Gajek, Arkadiusz; Marczak, Agnieszka; Mikula, Michal; Ostrowski, Jerzy; Sliwinska, Agnieszka; Rogalska, Aneta.

Afiliação

Gralewska P; Department of Medical Biophysics, Faculty of Biology and Environmental Protection, Institute of Biophysics, University of Lodz, 90-236 Lodz, Poland.
Gajek A; Department of Medical Biophysics, Faculty of Biology and Environmental Protection, Institute of Biophysics, University of Lodz, 90-236 Lodz, Poland.
Marczak A; Department of Medical Biophysics, Faculty of Biology and Environmental Protection, Institute of Biophysics, University of Lodz, 90-236 Lodz, Poland.
Mikula M; Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Ostrowski J; Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Sliwinska A; Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.
Rogalska A; Department of Nucleic Acid Biochemistry, Medical University of Lodz, 92-213 Lodz, Poland.

Int J Mol Sci ; 21(24)2020 Dec 19.

Article em En | MEDLINE | ID: mdl-33352723

Assuntos

Proteínas Mutadas de Ataxia Telangiectasia/antagonistas & inibidores; Quinase 1 do Ponto de Checagem/antagonistas & inibidores; Cistadenocarcinoma Seroso/patologia; Recombinação Homóloga; Neoplasias Ovarianas/patologia; Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia; Mutações Sintéticas Letais; Proteínas Mutadas de Ataxia Telangiectasia/genética; Proteínas Mutadas de Ataxia Telangiectasia/metabolismo; Proteína BRCA1/genética; Proteína BRCA2/genética; Quinase 1 do Ponto de Checagem/genética; Quinase 1 do Ponto de Checagem/metabolismo; Cistadenocarcinoma Seroso/tratamento farmacológico; Cistadenocarcinoma Seroso/genética; Feminino; Humanos; Neoplasias Ovarianas/tratamento farmacológico; Neoplasias Ovarianas/genética; RNA Interferente Pequeno/genética; Transdução de Sinais

Palavras-chave

ATR inhibitor; CHK1 inhibitor; PARP inhibitor; ovarian cancer; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cistadenocarcinoma Seroso / Recombinação Homóloga / Proteínas Mutadas de Ataxia Telangiectasia / Inibidores de Poli(ADP-Ribose) Polimerases / Quinase 1 do Ponto de Checagem / Mutações Sintéticas Letais Limite: Female / Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google